The FT819 data showing efficacy without conditioning chemotherapy is a significant differentiator in the competitive CAR T landscape. Monitor for additional FT819 dose level 2 data and potential regulatory alignment for registrational path. FT839 and FT836 preclinical data support pipeline optionality but are early stage.
Price Chart
Executive Summary
Fate Therapeutics presented clinical and preclinical data at ASGCT 2026 for its off-the-shelf iPSC-derived CAR T-cell programs. FT819 showed 3/3 SLE patients achieving SRI-4 and 2/3 achieving LLDAS with durable B-cell remodeling up to 12 months without conditioning chemotherapy. Preclinical data for FT839 and FT836 demonstrated broad depletion of pathogenic cells and synergy with standard-of-care therapies. The data supports the company's platform approach to eliminate conditioning chemotherapy, potentially expanding patient access.
Key Facts
- FT819: 3/3 SLE patients achieved SRI-4, 2/3 achieved LLDAS at dose level 1 without conditioning chemotherapy.
- FT819: 79% average depletion of major B cell clones lasting up to 12 months post single dose.
- FT839 preclinical: >99% depletion of B cells, plasmablasts, plasma cells; >90% depletion of activated T cells in RA and SLE samples.
- FT839: Persistence enhanced ~60x vs. unmodified CAR T via Sword and Shield technology.
- FT836 preclinical: Up to 100% tumor control in xenograft models as monotherapy or with mAbs; cytolytic activity enhanced ~5x with chemo/radiotherapy.
- FT836: Phase 1 clinical trials ongoing in solid tumors (NCT07216105) and multiple myeloma (NCT07221032).
- FT819 dose level 2 (900M cells) enrollment initiated.
Financial Impact
No financial figures disclosed in press release. Positive clinical data may support future regulatory filings and partnership opportunities.
Risk Factors
- Clinical data is early-stage (Phase 1, small sample size) and may not replicate in larger trials.
- FT819 dose level 2 data not yet available; higher doses may have safety or efficacy issues.
- FT839 and FT836 are preclinical; clinical validation is years away.
- Company has no approved products and relies on future financing or partnerships.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291886 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Press Release | $2.57 $2.34 | ▼ −8.95% | ▼ −6.96% | $2.31 (−10.31%) |
Aug 13, 2026 7w ago | 8-K | $2.52 $2.31 | ▼ −8.33% | ▼ −6.59% | $2.31 (−8.53%) |
Aug 5, 2026 8w ago | Insider Cluster | $2.49 $2.42 | ▲ +2.81% | ▲ +3.41% | $2.31 (+7.43%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.97 $3.11 | ▼ −57.87% | ▼ −55.98% | $2.31 (−17.01%) |
Jun 4, 2026 17w ago | 8-K | $1.98 $2.99 | ▲ +51.01% | ▲ +49.15% | $2.31 (+16.41%) |
Jun 1, 2026 17w ago | Press Release | $2.74 $2.70 | ▼ −1.46% | ▼ −0.16% | $2.31 (−15.88%) |
May 13, 2026 20w ago | 8-K | $2.14 $1.97 | ▼ −7.94% | ▼ −7.33% | $2.31 (+7.71%) |
May 11, 2026 20w ago | Press Release | $2.18 $1.90 | ▼ −12.84% | ▼ −12.54% | $2.31 (+5.73%) |
Apr 24, 2026 22w ago | DEFA14A | $1.31 $2.15 | ▲ +64.12% | ▲ +59.17% | $2.31 (+75.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access